Next Article in Journal
Solid Lipid Nanoparticles Loaded with Glucocorticoids Protect Auditory Cells from Cisplatin-Induced Ototoxicity
Next Article in Special Issue
Increased Citrullinated Histone H3 Levels in the Early Post-Resuscitative Period Are Associated with Poor Neurologic Function in Cardiac Arrest Survivors—A Prospective Observational Study
Previous Article in Journal
A Systematic Review and Meta-Analysis of the Accuracy of in Vivo Reflectance Confocal Microscopy for the Diagnosis of Primary Basal Cell Carcinoma
Previous Article in Special Issue
A Mechanistic and Pathophysiological Approach for Stroke Associated with Drugs of Abuse
Open AccessArticle

Altered Metabolomic Profile in Patients with Peripheral Artery Disease

1
Department of Nutrition, Food and Exercise Sciences, Florida State University, Tallahassee, FL 32306, USA
2
Department of Environmental Science, Baylor University, Waco, TX 76798, USA
3
Department of Surgery, University of Nebraska at Medical Center, Omaha, NE 68198, USA
4
Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE 68198, USA
5
Department of Surgery, Baylor Scott and White Hospital, Temple, TX 76508, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(9), 1463; https://doi.org/10.3390/jcm8091463
Received: 24 August 2019 / Revised: 11 September 2019 / Accepted: 12 September 2019 / Published: 14 September 2019
Peripheral artery disease (PAD) is a common atherosclerotic disease characterized by narrowed or blocked arteries in the lower extremities. Circulating serum biomarkers can provide significant insight regarding the disease progression. Here, we explore the metabolomics signatures associated with different stages of PAD and investigate potential mechanisms of the disease. We compared the serum metabolites of a cohort of 26 PAD patients presenting with claudication and 26 PAD patients presenting with critical limb ischemia (CLI) to those of 26 non-PAD controls. A difference between the metabolite profiles of PAD patients from non-PAD controls was observed for several amino acids, acylcarnitines, ceramides, and cholesteryl esters. Furthermore, our data demonstrate that patients with CLI possess an altered metabolomic signature different from that of both claudicants and non-PAD controls. These findings provide new insight into the pathophysiology of PAD and may help develop future diagnostic procedures and therapies for PAD patients. View Full-Text
Keywords: peripheral artery disease (PAD); metabolomics; claudication; critical limb ischemia (CLI) peripheral artery disease (PAD); metabolomics; claudication; critical limb ischemia (CLI)
Show Figures

Figure 1

MDPI and ACS Style

Ismaeel, A.; Franco, M.E.; Lavado, R.; Papoutsi, E.; Casale, G.P.; Fuglestad, M.; Mietus, C.J.; Haynatzki, G.R.; Smith, R.S.; Bohannon, W.T.; Sawicki, I.; Pipinos, I.I.; Koutakis, P. Altered Metabolomic Profile in Patients with Peripheral Artery Disease. J. Clin. Med. 2019, 8, 1463.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop